Estey E H, Kantarjian H, Keating M
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Semin Oncol. 1993 Dec;20(6 Suppl 8):1-5.
Combination therapy with idarubicin plus continuous-infusion, high-dose cytarabine in patients with newly diagnosed acute myelogenous leukemia resulted in an improved complete response rate over historic controls who received either (1) Adriamycin or amsacrine in combination with standard-dose cytarabine or (2) continuous-infusion, high-dose cytarabine alone or in combination with amsacrine or mitoxantrone. The complete response rate in patients with acute myelogenous leukemia was similar to that in patients with refractory anemia with excess blasts in transformation.
对于新诊断的急性髓性白血病患者，采用伊达比星联合持续静脉输注大剂量阿糖胞苷的联合治疗方案，与接受以下治疗的历史对照患者相比，完全缓解率有所提高：(1) 阿霉素或安吖啶联合标准剂量阿糖胞苷；(2) 单独使用持续静脉输注大剂量阿糖胞苷或与安吖啶或米托蒽醌联合使用。急性髓性白血病患者的完全缓解率与难治性贫血伴原始细胞过多转化患者的完全缓解率相似。
